Neuromed is a biopharmaceutical company focused on developing and commercializing pain therapies. The Company has a two-pronged strategy to enhance the commercial attractiveness of existing pain therapies and develop novel small molecule pain drugs. We have three programs aimed at addressing this important unmet medical need. Our lead product, NMED-1077 (OROSŪ Hydromorphone), is an extended release formulation of hydromorphone in Phase 3 clinical development. Neuromed is also developing oral drug candidates to block N-type calcium channels, a new and important target directly involved in pain signaling. Our third program is focused on producing promising T-type calcium channel blockers aimed at treating pain, epilepsy and hypertension.
Keywords: OROS Hydromorphone, pharmaceutical, calcium channel, pain therapeutics, pain reliever, biopharmaceutical, biotechnology, NMED-1077